SEP-10(2)

This issue contains a special bonus, but first we take a look at two recent EU court decisions. Kent Bernard, Sean-Paul Brankin, and Kristina Nordlander & Patrick Harrison analyze the (at long last!) judgment on AstraZeneca, raising real concerns about the future of legal protection for IP and R&D. Angela Laghezza contributes some initial insight into the “just-off-the-presses” decision on Akzo and how this will affect in-house counsel privilege. Then we̵